Introduction to the Mentor
Professor Jianxing He, PhD Supervisor, is the Director of the Guangzhou Institute of Respiratory Health and the Director of the National Center for Respiratory Medicine. He is also a leading scientist at the Guangzhou National Laboratory, whose primary research focuses on the early diagnosis and complex treatment of lung cancer in thoracic surgery, as well as the treatment of end-stage lung diseases such as advanced chronic obstructive pulmonary disease (COPD) and interstitial lung disease. He has pioneered three internationally recognized technological systems:
- Tubeless minimally invasive techniques, including autonomous ventilation lung transplantation and tracheal reconstruction (selected by Harvard University for Anesthesiology in 2022 and Tracheal Surgery in 2025).
- An intelligent screening, diagnosis, treatment, and rehabilitation system for lung cancer.
- Heterotopic heart-lung combined transplantation technology.
He innovatively proposed the HE’s Ventilation Mode for thoracic surgery and the theory of secondary injury and prevention in lung transplant donors, and promoted the rapid recovery technology for organ transplantation centered on tubeless techniques.
He has published 675 papers in journals such as NEJM and Lancet, with over 38,000 citations, and has been listed on Elsevier’s Lifetime Scientific Influence Rankings. He has been awarded numerous honors, including National Model Teacher, National Outstanding Physician, State Council Special Allowance Expert, National May 1st Labor Medal, and China's Top Ten Reputable Doctors. He has also received the National Science and Technology Progress First Prize (Innovation Team Award), the National Science and Technology Progress Second Prize, the National Innovation Excellence Award, the Ho Leung Ho Lee Prize, the Shulan Medical Award, and over 20 provincial and ministerial awards in China, including the Guangdong Science and Technology Progress First Prize.
Prof. He’s team consists of more than 30 senior thoracic experts and a multidisciplinary collaboration group. They perform over 12,000 lung cancer surgeries annually and have extensive experience in nearly 1,000 lung, heart-lung, and tracheal transplant surgeries. The team has developed medical-engineering integrated software and hardware products, including auxiliary diagnostic tools with over 90% accuracy for early diagnosis of pulmonary nodules smaller than 1.0 cm, artificial intelligence (AI) tools for lung and mediastinal tumor screening, a glass-free 3D visual surgical operation display system, and a decision-making system for postoperative therapy in lung cancer surgeries. These innovations have significantly improved the long-term survival rates of patients with early-stage lung cancer (primarily pulmonary nodules) and mid-stage lung cancer (primarily tracheobronchial tumors). The team has also pioneered multiple lung/tracheal transplant surgeries, pushing the boundaries of life-saving capabilities.
Desirable Criteria
1. Education and Age:
- Hold a Ph.D. in oncology, genetics, genomics, immunology, biomedical science, bioinformatics, organ transplantation, AI (including statistical machine learning, deep learning, large language models), or related fields, with the degree obtained within the last 3 years. Applicants should generally be under 35 years old.
- For non-first-time postdoctoral candidates, the previous postdoctoral assessment should be qualified or above.
- In principle, in-service personnel are not recruited for postdoctoral research.
2. Research Capabilities:
- Possess a certain level of English reading and writing skills, with experience publishing high-quality SCI papers as the first or corresponding author. Priority will be given to those who have published in internationally renowned journals.
3. Personal Qualities:
- Physically and mentally healthy, passionate about scientific research, diligent, and reliable. Strong teamwork spirit and independent working ability, with good academic ethics and a rigorous scientific attitude.
4. Professional Background (meet any one of the following):
- Priority will be given to those with experience in tumor genetics or rejection research in allogeneic/xenogeneic organ transplantation.
- Strong background in bioinformatics, including computer deep learning, database construction, genomics, and omics algorithm development.
- Published high-level papers as the first author in fields such as natural language processing, computer vision, or machine learning. Familiarity with large model application technology and experience in smart healthcare research is preferred.
Further Information
1. Salary:
Based on the high-quality papers published (or accepted) within the 3 years prior to the postdoctoral candidate's entry, the salary is divided into three tiers:
- Tier I: Pre-tax annual salary of approximately 450,000 RMB (including the employer’s portion of housing provident fund).
- Tier II: Pre-tax annual salary of approximately 390,000 RMB (including the employer’s portion of housing provident fund).
- Tier III: Pre-tax annual salary of approximately 330,000 RMB (including the employer’s portion of housing provident fund).
2. Additional Benefits:
- Research rewards: Outstanding performance during the postdoctoral period will be rewarded with 50,000 to 150,000 RMB.
- Research start-up funding: 200,000 RMB.
- Relocation allowance: Postdoctoral fellows who remain at the hospital after completing their term can apply for a 300,000 RMB relocation allowance from Guangzhou City.
- Support for applying for Guangzhou’s high-level talent programs. Outstanding postdoctoral fellows who remain at the hospital will be prioritized for inclusion in the “Nanshan Talent Project - Rising Star Program” with corresponding support.
CONTACT DETAILS
Email: liuseven0801@163.com
Attn: Ms. Liu